{'fraction_non_alphanumeric': 0.04846335697399527, 'fraction_numerical': 0.04018912529550828, 'mean_word_length': 4.5359477124183005, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MP55-11 MODIFIED IMMUNOSCORE IMPROVES PREDICTION OF SURVIVAL OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER

8/3/11 cases, respectively. As shown in figure, patient with OR had significantly higher PY than those without OR (43 vs. 17, P [ 0.04). AUC of PY for predicting OR was 0.74. Odds ratio per one PY was 1.03 (P [ 0.04). The cut-off value of PY to best predict OR was 36. At this cut-off, sensitivity, specificity, positive predictive value, and negative predictive value for OR of pembrolizumab were 73%, 79%, 73%, and 79%, respectively. There was no significant association between OR and variables other than smoking history. CONCLUSIONS: This is the first study to demonstrate an impact of smoking history on response to pembrolizumab in aUC. Heavy smoking history may predict favorable response to pembrolizumab.